This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ritchie, C. K. Articles by Fitzpatrick, L. A. Search for Related Content PubMed PubMed Citation Articles by Ritchie, C. K. Articles by Fitzpatrick, L. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Prostate Cancer

The Effects of Growth Factors Associated with Osteoblasts on Prostate Carcinoma Proliferation and Chemotaxis: Implications for the Development of Metastatic Disease¹

Endocrine Research Unit, Department of Internal Medicine and the Department of Biochemistry and Molecular Biology, Mayo Clinic and Mayo Foundation, Rochester Minnesota 55905

Address all correspondence and requests for reprints to: Lorraine A. Fitzpatrick, M.D., 5–164 West Joseph, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905.

The extensive mortality and morbidity associated with prostate cancer is caused by the high prevalence of metastatic disease at the time of diagnosis. The area most frequently involved in metastatic prostate cancer is the skeleton. Unlike other cancers, which metastasize to bone and destroy the bone matrix, prostate cancer is unique in that it is osteogenic, resulting in the formation of dense, sclerotic bone with high levels of osteoblastic activity. We proposed that factors produced by bone cells may be responsible for the development of prostate carcinoma metastasis. We studied the effects of these growth factors on prostate cell proliferation by [³H]thymidine incorporation and chemotaxis by the double-filter chamber method. Three prostate carcinoma cell lines were studied, LNCaP (androgen responsive) and PC-3 and DU-145 (androgen unresponsive). The bone-associated growth factors tested were: insulin-like growth factors I and II (IGF-I, IGF-II), transforming growth factor ß, interleukin (IL)-1ß, IL-6, and tumor necrosis factor (TNF-). IGF-I and IGF-II significantly increased proliferation in all three cell lines, whereas IL-6, TNF-, and IL-1ß significantly decreased proliferation. Transforming growth factor ß induced a biphasic response in proliferation in DU-145 and PC-3 cells and produced no response on LNCaP cells. Increased cell chemotaxis occurred in the presence of IGF-I and IGF-II, and decreased cell chemotaxis occurred with the addition of TNF- and IL-1ß. These data indicate that growth factors produced by bone cells alter prostate carcinoma cell proliferation and chemotaxis and suggest that modulations of the production of these factors may be a potential therapeutic intervention in deterring the metastasis of prostate carcinoma to bone.

This article has been cited by other articles:

				G. Wang, S. Haile, B. Comuzzi, A. H. Tien, J. Wang, T. M.K. Yong, A. E. Jelescu-Bodos, N. Blaszczyk, R. L. Vessella, B. A. Masri, et al. Osteoblast-Derived Factors Induce an Expression Signature that Identifies Prostate Cancer Metastasis and Hormonal Progression Cancer Res., April 15, 2009; 69(8): 3433 - 3442. [Abstract] [Full Text] [PDF]

				C. M. van Golen, T. S. Schwab, B. Kim, M. E. Soules, S. Su Oh, K. Fung, K. L. van Golen, and E. L. Feldman Insulin-Like Growth Factor-I Receptor Expression Regulates Neuroblastoma Metastasis to Bone. Cancer Res., July 1, 2006; 66(13): 6570 - 6578. [Abstract] [Full Text] [PDF]

				L. Wallner, J. Dai, J. Escara-Wilke, J. Zhang, Z. Yao, Y. Lu, M. Trikha, J. A. Nemeth, M. H. Zaki, and E. T. Keller Inhibition of Interleukin-6 with CNTO328, an Anti-Interleukin-6 Monoclonal Antibody, Inhibits Conversion of Androgen-Dependent Prostate Cancer to an Androgen-Independent Phenotype in Orchiectomized Mice. Cancer Res., March 15, 2006; 66(6): 3087 - 3095. [Abstract] [Full Text] [PDF]

				N. Blaszczyk, B. A. Masri, N. R. Mawji, T. Ueda, G. McAlinden, C. P. Duncan, N. Bruchovsky, H.-U. Schweikert, D. Schnabel, E. C. Jones, et al. Osteoblast-Derived Factors Induce Androgen-Independent Proliferation and Expression of Prostate-Specific Antigen in Human Prostate Cancer Cells Clin. Cancer Res., March 1, 2004; 10(5): 1860 - 1869. [Abstract] [Full Text] [PDF]

				K. Fizazi, J. Yang, S. Peleg, C. R. Sikes, E. L. Kreimann, D. Daliani, M. Olive, K. A. Raymond, T. J. Janus, C. J. Logothetis, et al. Prostate Cancer Cells-Osteoblast Interaction Shifts Expression of Growth/Survival-related Genes in Prostate Cancer and Reduces Expression of Osteoprotegerin in Osteoblasts Clin. Cancer Res., July 1, 2003; 9(7): 2587 - 2597. [Abstract] [Full Text] [PDF]

				H. Steiner, S. Godoy-Tundidor, H. Rogatsch, A. P. Berger, D. Fuchs, B. Comuzzi, G. Bartsch, A. Hobisch, and Z. Culig Accelerated in Vivo Growth of Prostate Tumors that Up-Regulate Interleukin-6 Is Associated with Reduced Retinoblastoma Protein Expression and Activation of the Mitogen-Activated Protein Kinase Pathway Am. J. Pathol., February 1, 2003; 162(2): 655 - 663. [Abstract] [Full Text] [PDF]

				T. Ueda, N. Bruchovsky, and M. D. Sadar Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways J. Biol. Chem., February 22, 2002; 277(9): 7076 - 7085. [Abstract] [Full Text] [PDF]

				A. Hobisch, R. Ramoner, D. Fuchs, S. Godoy-Tundidor, G. Bartsch, H. Klocker, and Z. Culig Prostate Cancer Cells (LNCaP) Generated after Long-Term Interleukin 6 (IL-6) Treatment Express IL-6 and Acquire an IL-6 Partially Resistant Phenotype Clin. Cancer Res., September 1, 2001; 7(9): 2941 - 2948. [Abstract] [Full Text] [PDF]

				M. V. Lee, E. M. Fong, F. R. Singer, and R. S. Guenette Bisphosphonate Treatment Inhibits the Growth of Prostate Cancer Cells Cancer Res., March 1, 2001; 61(6): 2602 - 2608. [Abstract] [Full Text]

				V. J. Csernus, A. V. Schally, H. Kiaris, and P. Armatis Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro PNAS, March 16, 1999; 96(6): 3098 - 3103. [Abstract] [Full Text] [PDF]

				M. Montagnani Marelli, R. M. Moretti, D. Dondi, M. Motta, and P. Limonta Luteinizing Hormone-Releasing Hormone Agonists Interfere with the Mitogenic Activity of the Insulin-Like Growth Factor System in Androgen-Independent Prostate Cancer Cells Endocrinology, January 1, 1999; 140(1): 329 - 334. [Abstract] [Full Text]

				T. Putz, Z. Culig, I. E. Eder, C. Nessler-Menardi, G. Bartsch, H. Grunicke, F. Uberall, and H. Klocker Epidermal Growth Factor (EGF) Receptor Blockade Inhibits the Action of EGF, Insulin-like Growth Factor I, and a Protein Kinase A Activator on the Mitogen-activated Protein Kinase Pathway in Prostate Cancer Cell Lines Cancer Res., January 1, 1999; 59(1): 227 - 233. [Abstract] [Full Text] [PDF]

				M. J. Gerdes, T. D. Dang, M. Larsen, and D. R. Rowley Transforming Growth Factor-{beta}1 Induces Nuclear to Cytoplasmic Distribution of Androgen Receptor and Inhibits Androgen Response in Prostate Smooth Muscle Cells Endocrinology, August 1, 1998; 139(8): 3569 - 3577. [Abstract] [Full Text] [PDF]